First total synthesis of (+)-3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN) from a non-carbohydrate source

Martin Banwell,*a[†] Chris De Savi^a and Keith Watson^b

^a Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, ACT 0200, Australia

^b Biota Chemistry Laboratory, Chemistry Department, Monash University, Clayton, Victoria 3168, Australia

Enantiopure *cis*-1,2-dihydrocatechol 2, a product obtained by microbial oxidation of chlorobenzene, has been converted into KDN 1 *via* a ten step reaction sequence.

In 1986 Inoue isolated the deaminated sialic acid (+)-3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN, 1) from the



membrane polysialoglycoproteins of rainbow trout eggs.1 Since KDN is likely responsible for protection of the egg membrane from attack by bacterial sialidases,² this compound is of interest as a sialic acid analogue that could be incorporated into other biologically relevant glycoproteins in order to protect them against sialidase activation by certain bacteria.³ Such possibilities have sparked considerable interest in KDN glycoscience with the result that several syntheses of the title compound have now been reported.1,4 All of these involve elaboration of carbohydrate-based starting materials. We now describe the first total synthesis of KDN from a non-carbohydrate source. The reaction sequence used will enable the preparation of novel analogues including those which incorporate ¹⁷O-, ¹³C- and/or ²H-labels in various combinations. Such analogues⁵ should be useful for probing the biological role(s) of KDN and related carbohydrate natural products.

The reaction sequence leading to compound 1 was inspired by the seminal work of Hudlicky and co-workers who have demonstrated the value of cis-1,2-dihydrocatechols as starting materials for the synthesis of various pentoses and hexoses.^{6,7} In the present work (Scheme 1) the cis-1,2-dihydrocatechol 2, which is obtained in >99% ee via microbial oxidation of chlorobenzene, was used. Thus, the acetonide derivative, 3,8 of compound 2 underwent regioselective and diastereofaciallyselective *cis*-dihydroxylation on reaction with osmium tetraoxide and the resulting diol 48 was reacted with 2,2-dimethoxypropane in the presence of toluene-p-sulfonic acid (TsOH) to give the bis-acetonide 5[‡] {99%, $[\alpha]_D$ + 68 (c 3.4)§}. Surprisingly, this last compound failed to react with ozone, perhaps because both faces of the π -bond are hindered by the endo-methyl groups associated with the adjacent 1,3-dioxolane rings. To circumvent such difficulties, diol 4 was converted into the corresponding bis(tert-butyldimethylsilyl ether) 69 {83%, mp <25 °C, $[\alpha]_D$ – 56 (c 6.4)} which underwent smooth ozonolytic cleavage to give, after a reductive work-up with NaBH₄, the ester alcohol 7 {99%, $[\alpha]_{D}$ + 12 (*c* 6.8)}. The *tert*butyldimethylsilyl ether derivative, 8 {100%, $[\alpha]_{D}$ + 2 (c 1.5)}, of the latter compound was then prepared in quantitative yield by standard methods. This compound was converted, over two conventional steps, into the unstable D-mannose derivative 9

{87% from **8**, $[\alpha]_D + 14$ (*c* 5.8)}. Reaction of compound **9** with Vasella's pyruvate anion equivalent **10**,^{10,11} under conditions we have used previously,¹² gave a *ca*. 2:3 mixture of the *syn*-and *anti*-addition products, **11** {37%, $[\alpha]_D + 10$ (*c* 1.9)} and **12**



Scheme 1 Reagents and conditions: i, see ref. 8; ii, see ref. 8; iii, $Me_2C(OMe)_2$, TsOH (cat.), 18 °C, 1.0 h; iv, TBDMSCI (4 equiv.), imidazole (5 equiv.), DMF, 18 °C, 16 h; v, O₃, MeOH, -78 to 0 °C, 0.1 h, then NaBH₄ (4 equiv.), 18 °C, 2 h; vi, TBDMSOTf (1.5 equiv.), 2,6-lutidine (3 equiv.), CH₂Cl₂, 0 to 18 °C, 16 h; vii, LAH (1.5 equiv.), THF, -10 °C, 2 h; viii, (COCl)₂ (1.2 equiv.), DMSO, CH₂Cl₂, -78 to 0 °C, 1 h, then Et₃N (2.6 equiv.); ix, Zn dust (4.0 equiv.), sat. aq. NH₄Cl, THF, 0 to 18 °C, 1.5 h; x, O₃, MeOH, -78 °C, 0.033 h, then Me₂S (5 equiv.), -78 to 18 °C, 2 h; xi, 4 : 1 TFA-H₂O, 18 °C, 18 h; xii, Dowex 50W resin (H⁺ form), MeOH, 6 h, 18 °C, then Ac₂O (10 equiv.), DMAP (trace), pyridine, 18 °C, 20 h

Chem. Commun., 1998 1189

 $\{52\%, [\alpha]_{\rm D} + 16 (c \ 1.6)\}$, respectively. The components of this mixture were readily separated from one another by semipreparative HPLC and compound 11 was then subjected to reaction with ozone. In this way the α -keto ester 13 {98%, $[\alpha]_D$ +5 (c 2.2) was obtained. Treatment of compound 13 with 4:1 TFA-water at 18 °C for 16 h resulted in deprotection of all the hydroxy groups as well as cyclisation to give KDN which was identical, as judged by ¹H NMR analysis, with an authentic sample prepared by enzymatic methods.^{4g} For the purposes of further spectroscopic characterisation, KDN was esterified using MeOH and the intermediate methyl ester subjected to exhaustive acetylation. In this way the KDN derivative 1413 {68% from 13, mp 100–104 °C; lit.,¹³ 104–105 °C; $[\alpha]_{\rm D} - 17$ (*c* 1.9); lit.,¹³ – 20 (*c* 0.7)} was obtained and the structure of this compound follows from spectroscopic data.¶ In addition, this material proved identical with a sample {[α]_D - 17 (c 1.2)} prepared from authentic KDN. Interestingly, while ozonylitic cleavage of compound 12 gave 4-epi-13 {98%, $[\alpha]_{\rm D}$ + 17 (c 5.0)}, sequential treatment of the latter compound with TFAwater, acidic MeOH then Ac₂O-pyridine only gave a complex mixture of uncharacterisable products.

We thank the Institute of Advanced Studies for financial support and the ARC for the provision of an APA (Industry) Scholarship to C. D. S. Dr Gregg Whited (Genencor International Inc.) is thanked for providing generous quantities of diol **2**.

Notes and References

† E-mail: mgb@rsc.anu.edu.au

[‡] All new and stable compounds had spectroscopic data [IR, UV, NMR, mass spectrum] consistent with the assigned structure. Satisfactory combustion and/or high resolution mass spectral analytical data were obtained for new compounds and/or suitable derivatives.

§ All optical rotations were determined in CHCl₃ at 20 °C.

§ Selected data for **14**: δ_H(300 MHz, CDCl₃) 5.40 (dd, *J* 6.4 and 2.3, 1 H), 5.27 (m, 1 H), 5.15 (dt, *J* 6.0 and 2.5, 1 H), 4.97 (t, *J* 9.7, 1 H), 4.43 (dd, *J* 12.2 and 2.2, 1 H), 4.19 (dd, *J* 10.1 and 2.4 Hz, 1 H), 4.14 (dd, *J* 12.2 and 5.8, 1 H), 3.78 (s, 3 H), 2.63 (dd, *J* 13.7 and 5.3, 1 H), 2.08 (obscured multiplet, 1 H), 2.16 (s, 3 H), 2.12 (s, 3 H), 2.07 (s, 3 H), 2.04 (s, 3 H), 2.02 (s, 3 H), 2.01 (s, 3 H); $\delta_{\rm C}$ (75 MHz, CDCl₃) 170.6, 170.1, 170.0, 169.7, 169.6, 168.2, 166.0, 97.2, 71.4, 70.1, 68.7, 67.3, 66.8, 61.8, 53.2, 35.4, 20.8, 20.7, 20.6 (3 methyl carbon resonances obscured or overlapping); $v_{\rm max}({\rm KBr}/{\rm cm^{-1}}$ 2961, 1750, 1437, 1372, 1233, 1169, 1114, 1055, 1013, 946; *m*/z (EI, 70 eV) 534 (M⁺⁺, <1%), 433 (100), 373 (100) [HRMS: Calc. for C₂₂H₃₀O₁₅ (M⁺⁺), 534.1585. Found: 534.1583].

- 1 D. Nadano, M. Iwasaki, S. Endo, K. Kitajima, S. Inoue and Y. Inoue, J. Biol. Chem., 1986, 261, 11 550.
- 2 E. Schreiner and E. Zbiral, Liebigs Ann. Chem., 1990, 581.
- 3 K. Kitajima, Bio. Ind., 1997, 14, 11 and references cited therein.

- 4 (a) H. Tsukamoto and T. Takahashi, *Tetrahedron Lett.*, 1997, 38, 6415;
 (b) T.-H. Chan and M.-C. Lee, J. Org. Chem., 1995, 60, 4228; (c) A. Dondoni, A. Marra and P. Merino, J. Am. Chem. Soc., 1994, 116, 3324; (d) K. Sato, T. Miyata, I. Tanai and Y. Yonezawa, Chem. Lett., 1994, 129; (e) M. Nakamura, K. Furuhata and H. Ogura, Chem. Pharm. Bull., 1988, 36, 4807; (f) R. Shirai, M. Nakamura, S. Hara, H. Takayanagi and H. Ogura, Tetrahedron Lett., 1988, 29, 4449. Various enzymatic methods for the preparation of KDN have been reported: see (g) T. Sugai, A. Kuboki, S. Hiramatsu, H. Okazaki and H. Ohta, Bull. Chem. Soc. Jpn., 1995, 68, 3581 and references cited therein.
- 5 For recent work concerned with the synthesis of KDN analogues, see: G. B. Kok, A. K. Norton and M. von Itzstein, *Synthesis*, 1997, 1185; G. B. Kok and M. von Itzstein, *Synthesis*, 1997, 769; X.-L. Sun, T. Kai, H. Takayanagi and K. Furuhata, *J. Carbohydr. Chem.*, 1997, 16, 541; T. Kai, X.-L. Sun, H. Takayanagi and K. Furuhata, *J. Carbohydr. Chem.*, 1997, 16, 521; T.-H. Chan, Y.-C. Xin and M. von Itzstein, *J. Org. Chem.*, 1997, 62, 3500; G. B. Kok, B. L. Mackey and M. von Itzstein, *Carbohydr. Res.*, 1996, 289, 67; A. Hasegawa, N. Suzuki, F. Kozawa, H. Ishida and M. Kiso, *J. Carbohydr. Chem.*, 1996, 15, 639.
- 6 For two excellent reviews, see T. Hudlicky, D. A. Entwistle, K. K. Pitzer and A. J. Thorpe, *Chem. Rev.*, 1996, **96**, 1195; T. Hudlicky, K. A. Abboud, D. A. Entwistle, R. Fan, R. Maurya, A. J. Thorpe, J. Bolonick and B. Myers, *Synthesis*, 1996, 897. See, also, F. Yan, B. V. Nguyen, C. York and T. Hudlicky, *Tetrahedron*, 1997, **53**, 11541; T. Hudlicky, K. K. Pitzer, M. R. Stabile, A. J. Thorpe and G. M. Whited, *J. Org. Chem.*, 1996, **61**, 4151.
- For reviews on the applications of *cis*-1,2-dihydrocatechols in synthesis, see ref. 6 and T. Hudlicky and A. J. Thorpe, *Chem. Commun*, 1996, 1993; T. Hudlicky and J. W. Reed, in *Advances in Asymmetric Synthesis*, ed. A. Hassner, JAI, Greenwich, CT, 1995, vol. 1, p. 271; S. M. Brown, and T. Hudlicky, in *Organic Synthesis: Theory and Applications*, ed. T. Hudlicky, JAI, Greenwich, CT, 1993, vol. 2, p. 113; H. A. J. Carless, *Tetrahedron: Asymmetry*, 1992, **3**, 795; D. A. Widdowson, D. W. Ribbons and S. D. Thomas, *Janssen Chimica Acta*, 1990, 3.
- 8 T. Hudlicky, M. Mandel, J. Rouden, R. S. Lee, B. Bachmann, T. Dudding, K. J. Yost and J. S. Merola, *J. Chem. Soc., Perkin Trans. 1*, 1994, 1553.
- 9 T. Hudlicky, F. Rulin, T. Tsunoda, H. Luna, C. Andersen and J. D. Price, *Isr. J. Chem.*, 1991, **31**, 229.
- 10 F. Baumberger and A. Vasella, *Helv. Chim. Acta*, 1986, **69**, 1205. For a review on, *inter alia*, pyruvate anion equivalents, see L. Kovács, *Recl. Trav. Chim. Pays-Bas*, 1993, **112**, 471.
- 11 Chan and Lee [ref. 4(b)] have used a closely related nucleophilic addition reaction in their synthesis of KDN.
- 12 M. Banwell, C. De Savi, D. Hockless and K. Watson, *Chem. Commun*, 1998, 645.
- 13 M. Nakamura, H. Takayanagi, K. Furuhata and H. Ogura, *Chem. Pharm Bull.*, 1992, **40**, 879; M. Nakamura, K. Furuhata, T. Yamasaki and H. Ogura, *Chem. Pharm. Bull.*, 1991, **39**, 3140; M. Nakamura, K. Furuhata, K. Yamazaki, H. Ogura, H. Kamiya and H. Ida, *Chem. Pharm Bull.*, 1989, **37**, 2204.

Received in Cambridge, UK, 9th March 1998; 8/01889H